Clinical trials: HIV Reservoir
Hiv
Tracking and Exploring the Source of Viral REbound
Phylogenic analysis of viruses hosted in marker positive reservoir cells including CD32a+ CD4 T lymphocytes and rebounding viruses after treatment interruption
- Trial name
- TESOVIR (NCT03117985)
- Testing
- no drug
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
HIV-1-infection
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably…
- Trial name
- HIV-1 (NCT04404049)
- Testing
- UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W
- Volunteers
- 39 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Human Immunodeficiency Virus (HIV)
The Effect of Ixazomib on the Latent HIV Reservoir
The primary purpose of the trial is to determine the safety and tolerability of ixazomib in HIV infected patients on antiretroviral therapy.
- Trial name
- NCT02946047
- Testing
- Ixazomib 1 MG, Ixazomib 2 MG, Ixazomib 3 MG
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
HIV
Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals
The BCN02-Romi study aims to evaluate a combined "kick and kill" strategy using the most immunogenic candidate vaccine available so far (HIVconsv) with the strongest latency reversal agent available at present time (romidepsin)…
- Trial name
- NCT02616874
- Testing
- MVA.HIVconsv vaccine, Romidepsin
- Where
- 2 sites in Spain
- Volunteers
- 15 people
- Sponsor
- IrsiCaixa